Valion Bio Inc（VBIO）の株式分析VBIOValion Bio Inc

Valion Bio, Inc., formerly Tivic Health Systems, Inc., is a late-stage immunotherapeutics company. The Company offers Entolimod, which is a drug used to treat acute radiation syndrome (ARS). Entolimod is a toll-like receptor 5 (TLR5) agonist that activates an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. Its pipeline also includes Entolimod to treat neutropenia and lymphocyte exhaustion, as well as Entolasta, an immunologically optimized variant of Entolimod for chronic applications. Its subsidiary, Velocity Bioworks, is a full-service contract development and manufacturing organization (CDMO) that is based in San Antonio, Texas. It offers upstream and downstream process development and optimization; analytical testing, assay development, and qualification; quality control and stability testing; microbial and mammalian expression systems; technology transfer and program management services. It operates in the Healthcare sector.

Tivic Health Systems, Inc. (VBIO) is not a good buy right now due to its extremely low current price of $0.94, a staggering year-to-date change of -97.31%, and an RSI of 9.661 indicating it is heavily oversold. The company is facing significant financial challenges, as evidenced by a net loss of $6.4 million in Q2 2026 and a gross margin of -99.32% in Q3 2025, which raises concerns about its viability. The main risk is the company's high operating expenses and declining cash reserves, with cash and equivalents dropping to $7.2 million from $12.6 million, suggesting liquidity issues.